Search

everythinglearnresearchcommunity

for

Search:↓

The user experienced increased shedding and an itchy scalp after switching from Ascend to Aurobindo finasteride. They are considering switching to dutasteride and are concerned about elevated estrogen levels and the effectiveness of adding minoxidil later.

The conversation discusses using scalp antiandrogens like RU58841, pyrilutamide, or fluridil on the face to reduce sebum production, noting that clascoterone (winlevi) is an approved facial antiandrogen with underwhelming reviews.

PP405 is likely fake, and JXL069 is an unrefined prototype with unknown side effects. It's advised to wait for the official PP405 release.

User asks if breaking open Eucapil (fluridil) ampule and using half is okay, and if leaving open vile overnight ruins it.

The conversation is about a user trying to fund lab testing for RU58841 to verify its legitimacy, as there are doubts about its effectiveness. Some users express skepticism about RU58841, suggesting alternatives like KX-826.

Breezula is expected to launch in late 2026, with data being sent to the FDA in early 2026. The process is typical for a successful trial.

The emotional difficulty of hair loss for men and how society can be more understanding; various methods to address hair loss, such as finasteride, minoxidil, and RU58841; and why it is important to normalize caring about one's looks.

The user experienced a slight decrease in hair shedding and scalp itch, and reduced sebum production using Pyrilutamide, but stopped due to chest pain, breathing difficulties, and heart issues. They felt normal a week after discontinuing and doubted FDA approval for the drug.

The conversation is about the effectiveness of Breezula for hair loss, with skepticism expressed due to lack of scientific proof and mixed results from those using Breezula and RU58841. Some are waiting for clinical trial results before trying treatments like Breezula and SM04554.

The conversation is about obtaining and the effectiveness of Olumiant for treating hair loss, specifically for someone with early-stage alopecia areata concerned about hair loss around the face. The user is seeking clarity on how to get a prescription for Olumiant.

RU58841 is effective when used once daily. Using it twice daily may require reducing the dosage, potentially decreasing its effectiveness.

KX-826 is being discussed for hair loss treatment, with users debating between 0.5% and 0.9% solutions and foam. Some report side effects like headaches, while others see no changes; it blocks androgen receptors without reducing DHT levels.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.

Balding's emotional impact is discussed, highlighting self-acceptance and well-being. Treatments like finasteride, minoxidil, and microneedling are mentioned, but the focus is on self-care and maintaining perspective.

The conversation is about the availability of a 2% Pyrilutamide treatment by Kintor for hair loss. A user confirms that it is not available.

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.

The conversation is about someone experiencing continued hair loss despite using Pyrilutamide and considering the need for more time or better quality control for the treatment. Another person suggests waiting for the drug to be officially approved due to potential quality issues with current products.

The conversation is about how dealing with hair loss has made other insecurities seem less significant. Some users shared experiences of self-acceptance and improvements in other areas, like vision correction, but still facing the challenge of hair loss.

KOSHINE826 is a new anti-hair loss and hair growth solution that claims to effectively control oil, reduce hair fall, and promote real hair growth. It targets androgenetic alopecia by inhibiting DHT and has shown promising results in clinical trials.

The conversation discusses the effectiveness and authenticity of RU58841 purchased from Amazon, with some users suggesting buying from reputable sources like Anagen Inc. Others recommend using oral finasteride instead of RU58841 due to concerns about product legitimacy.

Capilia Longa and Scandinavian Biolabs are discussed, with skepticism about their effectiveness and value. The conversation suggests avoiding these products due to high cost and perceived lack of results.

The conversation discusses hair shedding after switching from finasteride to dutasteride for hair loss treatment. Users suggest that shedding is a common and temporary phase, with results expected in about 6 to 8 months.

The user has been using topical finasteride and minoxidil for a month to address hair thinning. They are experiencing shedding but have noticed small hairs on their temples.

New hair loss treatments, including Breezula, VDPHL01, and PP405, are nearing Phase 3 trials, offering hope for effective solutions. Current treatments like finasteride and minoxidil remain effective, but early intervention is crucial.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115 release timeline is uncertain, with possible grey market availability in 2024-2025.

False information about hair loss is being spread, misleading people. Treatments like Minoxidil, finasteride, and RU58841 are not mentioned in the context of the misinformation.

The user experienced hair shedding after increasing minoxidil from 5% to 7% with latanoprost, possibly causing telogen effluvium. They are on HRT with Lupron, Estradiol, and Raloxifene, and are concerned about the shedding's duration.

The conversation discusses hair shedding experienced by users undergoing hair loss treatments, including finasteride, minoxidil, and microneedling. Many users report experiencing significant shedding around the 8-12 month mark, which is considered a normal part of the hair regrowth process, with expectations of stronger regrowth following the shedding phase.

A bald groom was beaten by the family of the bride for wearing a wig. The conversation discusses the cultural stigma around baldness in India and the consequences of deception in arranged marriages.